



Enzon to Present Data at EORTC-NCI-AACR

New data presented on novel pipeline

BRIDGEWATER, N.J., Nov 16, 2009 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that data from its pipeline programs will be presented at the 2009 EORTC-NCI-AACR (European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research) annual meeting being held November 16-19, 2009 in Boston, Massachusetts.

"We are pleased to present additional clinical data from our PEG-SN38 phase I program, as well as clinical data from our Survivin antagonist program," said Jeffrey H. Buchalter, president and chief executive officer of Enzon. "We are also excited to present preclinical data from our locked-nucleic acid (LNA) targets, the androgen receptor, b-catenin and GLI2 antagonists. These targets were selected based on the key role each play in the growth of many cancers."

Posters and Abstracts being presented include:

PEG-SN38 (EZN-2208)

Kurzrock et al: Phase 1, first-in-human, dose-escalation study of EZN-2208, a novel anticancer agent, in patients with advanced malignancies

Patnaik et al: EZN-2208, a novel anticancer agent, in patients with advanced malignancies: a Phase 1 dose-escalation study

Pastorino et al: EZN-2208, a novel PEGylated SN-38 drug conjugate, markedly inhibits tumor growth and metastatic spreading in preclinical models of human neuroblastoma

Survivin mRNA antagonist (EZN-3042)

Tolcher et al: EZN-3042 (E), a novel survival messenger ribonucleic acid (mRNA) antagonist, administered as a single agent (SA) or with docetaxel (D): results of a Phase 1, first-in-human, pharmacokinetic (PK), combination after single agent (CASA) dose-escalation study

Androgen receptor mRNA antagonist

Sapra et al: A locked nucleic acid antisense oligonucleotide against androgen receptor, down-modulates target mRNA and causes antitumor effects in xenograft models of prostate cancer

GLI2 mRNA antagonist

Zhang et al: LNA (locked nucleic acid) oligonucleotide based GLI2 RNA antagonist EZN-4482 effectively inhibited tumor growth and increased survival of animals with liver metastasis

b-catenin mRNA antagonist

Zhang et al: In vitro and in vivo characterization of two novel b-catenin RNA antagonists, EZN-3889 and 3892

LNA-based mRNA antagonists

Zhang et al: LNA (locked nucleic acid)-based RNA antagonists mediate target mRNA silencing without transfection by simple addition to cell culture media

The posters will be presented Wednesday evening. Details on the data presented will be announced at the conclusion of the meeting.

About Enzon

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing, manufacturing and commercializing important medicines for patients with cancer and other life-threatening conditions. The Company has a portfolio of four marketed products, Oncaspar(R), DepoCyt(R), Abelcet(R) and Adagen(R). Enzon's drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform and the Locked Nucleic Acid (LNA) technology. Enzon's PEGylation technology was used to develop two of its products, Oncaspar and Adagen, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden its revenue base. Further information about Enzon and this press release can be found on the Company's web site at www.enzon.com.

Forward Looking Statements

There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should," "potential," "anticipates," "plans" or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual

results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to: the timing, success and cost of clinical studies; the ability to obtain regulatory approval of products; market acceptance of, and continuing demand for, Enzon's products and the impact of competitive products and pricing. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2008. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Enzon does not intend to update this information.

SOURCE: Enzon Pharmaceuticals, Inc.

Enzon Pharmaceuticals, Inc.
Craig Tooman, 908-541-8777
EVP, Finance and
Chief Financial Officer

Copyright Business Wire 2009